The Centers for Medicare and Medicaid Services (CMS) has issued its final notice outlining the new Transitional Coverage for Emerging Technologies (TCET) Pathway.
This pathway for certain breakthrough devices as determined by the U.S. Food and Drug Administration (FDA) -- such as those related to imaging -- increases the number of national coverage determinations (NCDs) that the CMS will conduct per year. The CMS said this supports both improved patient care and innovation by providing a "clear, transparent, and consistent coverage process while maintaining robust safeguards" for the Medicare population.
The CMS added that it anticipates accepting up to five TCET candidates per year. For technologies accepted into and continuing in the TCET pathway, the CMS’ goal is to finalize an NCD within six months after FDA market authorization.
The full notice can be found here.
